Development of SGC-GAK-1 as an orally active in vivo probe for cyclin G associated kinase through cytochrome P450 inhibition
C. R. M. Asquith, J. M. Bennett, L. Su, T. Latinen, J. M. Elkins, J. E. Pickett, C. I. Wells, Z. Li, T. M. Willson, W. J. Zuercher
The paper develops SGC-GAK-1 as an orally active in vivo probe for GAK by using cytochrome P450 inhibition to improve its metabolic stability and plasma exposure.
bioRxiv · May 7, 2019 · PreprintPharmacology & Toxicology